logo
logo
MTD stock ticker logo

Mettler-Toledo International Inc.

NYSE•MTD
CEO: Mr. Patrick K. Kaltenbach
セクター: Healthcare
業種: Medical - Diagnostics & Research
上場日: 1997-11-14
Mettler-Toledo International Inc. manufactures and supplies precision instruments and services in the Americas, Europe, Asia, and internationally. It operates through five segments: U.S. Operations, Swiss Operations, Western European Operations, Chinese Operations, and Other. The company's laboratory instruments include laboratory balances, liquid pipetting solutions, automated laboratory reactors, real-time analytics, titrators, pH meters, process analytics sensors and analyzer technologies, physical value analyzers, density and refractometry, thermal analysis systems, and other analytical instruments; and LabX, a laboratory software platform to manage and analyze data generated from its instruments. Its industrial instruments comprise industrial weighing instruments and related terminals, automatic dimensional measurement and data capture solutions, vehicle scale systems, industrial software, metal detection equipment, x-ray systems, check weighing equipment, camera-based imaging equipment, track-and-trace solutions, and product inspection systems. The company's retail weighing solutions consist of weighing and software solutions, AI-driven image recognition solution, and automated packaging and labelling solutions for the meat backroom. It serves the life science industry, independent research organizations, and testing labs; food and beverage manufacturers; food retailers; chemical, specialty chemical, and cosmetics companies; food retailers; transportation and logistics, metals, and electronics industries; and the academic community through its direct sales force and indirect distribution channels. Mettler-Toledo International Inc. was incorporated in 1991 and is based in Columbus, Ohio.
連絡先情報
1900 Polaris Parkway, Columbus, OH, 43240, United States
614-438-4511
www.mt.com
時価総額
$22.86B
PER (TTM)
26.2
28.9
配当利回り
--
52週高値
$1.53K
52週安値
$1.02K
52週レンジ
22%
順位18Top 5.0%
6.3
F-Score
改良版 Piotroski 分析
10年ファンダメンタル
強い • 6.3 / 9 ポイント
スコアレンジ (0-9)
8-9: 価値が優れている
6-7: 基礎体質が強い
4-5: 全体的に堅調
0-3: パフォーマンスが弱い
データ期間: 2016-2025

財務ダッシュボード

Q1 2026 データ

売上高

$947.13M+0.00%
直近4四半期の推移

EPS

$8.35+0.00%
直近4四半期の推移

フリーCF

$122.38M+0.00%
直近4四半期の推移

2025 Annual 決算ハイライト

主なハイライト

Total Net Sales Growth Net sales reached $4.03B USD in 2025, increasing 4% in USD terms, despite soft end-market demand.
Strong Operating Cash Flow Cash provided by operating activities totaled $955.8M USD in 2025, supporting liquidity needs and capital expenditures.
Laboratory Segment Performance Laboratory products/services generated $2.24B USD, growing 3% in USD, driven by process analytics growth.
Sustained R&D Investment Research and development expenses were $199.4M USD in 2025, maintained at approximately 5.0% of net sales.

リスク要因

Gross Margin Erosion Risk Gross profit margin fell to 59.4% in 2025, reflecting higher tariff costs and unfavorable business mix impacts.
China Concentration Exposure China represents 16% of sales; geopolitical tensions and local economic challenges create significant operational risks.
Cybersecurity Infrastructure Risk Reliance on technology infrastructure creates vulnerability to sophisticated cyber attacks, potentially causing service interruptions and data loss.
Currency Volatility Exposure Strengthening Swiss franc against USD/Euro reduces earnings; 1% change impacts tax-excluded earnings by $2.8M–$3.1M annually.

見通し

Automation Digitalization Focus Expect continued benefit from market trends toward automation and digitalization, including customer replacement cycles into 2026.
Service Business Expansion Service business delivered strong results, expanding value-added offerings for uptime and regulatory compliance support globally.
Capital Allocation Strategy Board authorized additional $2.75B for share repurchases; $3.7B remaining availability as of year-end 2025.
Strategic Acquisition Focus Pursue "bolt-on" acquisitions leveraging global network, targeting life sciences and distribution channel expansion opportunities.

同業比較

売上高 (TTM)

HUM stock ticker logoHUM
$137.20B
+14.1%
IQV stock ticker logoIQV
$16.63B
+7.3%
LH stock ticker logoLH
$14.14B
+7.3%

粗利益率 (最新四半期)

ILMN stock ticker logoILMN
68.2%
-1.4pp
NTRA stock ticker logoNTRA
64.8%
+3.1pp
DXCM stock ticker logoDXCM
62.9%
+0.8pp

主要指標

銘柄コード
時価総額
PER (TTM)
ROE (TTM)
負債比率
HUM$45.53B40.46.2%25.3%
A$36.67B26.020.8%25.7%
ALC$32.58B39.93.7%16.6%

長期トレンド

直近4四半期
売上高
純利益
営業キャッシュフロー
4四半期売上高CAGR
-1.2%
横ばい
4四半期純利益CAGR
-5.7%
収益性の低下
キャッシュフロー安定性
100%
優れたキャッシュフローの実績

深度リサーチ

次回決算:2026年7月30日
|
EPS:$10.78
|
売上高:$1.03B
財務データ
決算説明会
財務レポート
ニュース
損益計算書
バランスシート
キャッシュフロー計算書
財務比率
変化率
損益計算書
直近12ヶ月
データなし